NIKKEI 225
37,690.91 -769.17 (-2.00%) HANG SENG
17,266.35 +65.08 (+0.38%) CRUDE OIL
82.95 +0.14 (+0.17%) GOLD FUTURES
2,329.20 -9.20 (-0.39%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,447.42 -2,166.74 (-4.04%)
Enzo Biochem, Inc. (ENZ)
After hours:
| Previous close | 1.0900 |
| Open | 1.1000 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 800 |
| Day's range | 1.0500 - 1.1000 |
| 52-week range | 1.0500 - 2.7400 |
| Volume | |
| Avg. volume | 108,491 |
| Market cap | 54.299M |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4700 |
| Earnings date | 12 Jun 2024 - 17 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Enzo Biochem (NYSE:ENZ) shareholders have endured a 69% loss from investing in the stock three years ago
Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of...
GlobeNewswireEnzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update
FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024. Second Quarter Highlights The Company's Life Science division's second-quarter revenue of $8.5 million improved year-over-year by 14%. During the 2024 period, we experienced a 25% revenue increase in the United States, driven by increased product demand in the drug development and cell and gene therapy mark
- GlobeNewswire
Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments
FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fiscal Year 2023 Annual Shareholder Meeting Proposals Proposal One – The shareholders elected Kara Cannon, Steven J. Pully, Bradley L. Radoff, and Mary Tagliaferri, M.D. to the Company’s Board of Directors to hold office for a term ending a
